Eli Lilly and Company
For nearly 150 years, we’ve made significant and game-changing progress on our mission to make life better for people around the world. We’ve remained headquartered in Indianapolis, Indiana, since our founding on May 10, 1876, but our employees now work in countries around the world.
And thanks to the dedication of our diverse global team, we’ve been able to answer the call for new medicines to help solve some of the world’s most significant health challenges
When you’re on a mission to do what’s never been done before, you seek people willing to challenge the status quo of medicine. Those willing to relentlessly pursue what’s next, all in the name of health above all. #WeAreLilly
We are Lilly
Why do our employees love coming to work each and every day? Here’s what they have to say.
47,000 global employees coming together from diverse backgrounds to create medicines that make life better for people around the world. Get to know Team Lilly through our Powered by Purpose series.
NEWS
It’s no secret that the pharmaceutical industry spends a significant amount of money lobbying state and federal governments to gain leverage that will benefit individual companies and the industry overall.
In October, the Minnesota Attorney General filed a lawsuit against three of the biggest insulin manufacturers over price gouging claims. One month later the American Diabetes Association published recommendations and public policy solutions.
The two companies inked a non-disclosure agreement on December 22, 2018 and amended it a day later. One of the things apparent is that the companies wanted to make a splash at the JPM conference.
Eli Lilly’s ANNOUNCE Phase III clinical trial of Lartruvo (olaratumab) in advanced or metastatic soft tissue sarcoma failed to meet the primary endpoints of overall survival.
In 2018, the FDA approved 59 novel drugs, meaning approved new molecular entities. BioSpace analyzed new drug approvals from 2014 to 2018 to determine which companies were responsible for the most drug approvals in that period. Here’s a look.
It didn’t take long for the new leadership structure in the U.S. House of Representatives to take on the pharmaceutical industry. On Monday, the House Committee on Oversight and Reform launched an investigation into prescription drug pricing practices.
Ahead of the JP Morgan Healthcare Conference, Jamie Dimon, chief executive officer of JP Morgan Chase, hosted a private dinner for biopharma executives Sunday night. Although the dinner was private, apparently one of the hot topics of discussion was a company not represented at the party—Amazon.
Tuesday, January 8, was another busy day in San Francisco for the JP Morgan Healthcare Conference. One interesting sideline was the idea that the current government shutdown could complicate some deals.
Days after acquiring Loxo Oncology, Eli Lilly Chief Executive Officer David Ricks outlined projections for the new year and said that he, and other executive leaders, feel confident about the position that the company now finds itself in during a fireside chat at the J.P. Morgan Healthcare Conference.
JOBS
IN THE PRESS